Featured Research

from universities, journals, and other organizations

Fighting cancer and steering immune reactions: New mechanism for reversible proteasome inhibition

Date:
December 27, 2010
Source:
Technische Universitaet Muenchen
Summary:
In their function as cellular recycling plants, proteasomes fulfill a life-sustaining role in all cells -- including cancer cells. When the proteasomes become inhibited, cells suffocate in their own waste. A recently discovered reversible proteasome inhibition may provide the key to more specific anti-cancer drugs and to controlling rejection reactions in transplantations.

The tiny alpha-keto-aldehyde-peptide fits a specific site on the proteasome like a key going into a lock and blocks the proteasome. However, unlike other inhibitors, the reaction of these two groups is reversible: The key can be removed from the lock and the proteasome can resume its work.
Credit: Prof. Dr. Michael Groll / TUM

In their function as cellular recycling plants, proteasomes fulfill a life-sustaining role in all cells -- including cancer cells. When the proteasomes become inhibited, cells suffocate in their own waste. A reversible proteasome inhibition recently discovered at the Technische Universitaet Muenchen may provide the key to more specific anti-cancer drugs and to controlling rejection reactions in transplantations. The international edition of Angewandte Chemie presents their results online ahead of print.

Related Articles


What makes cancer cells so dangerous is that they grow in an unregulated way and proliferate much faster than other cells. The proteasome, a large protein complex, plays a key role in this process: By breaking down used proteins for recycling, it clears the way for the next cycle. New hope was spawned several years ago with the discovery that inhibiting proteasomes can be used as a means to put the brakes on cell growth. In the mean time, the first drug using this approach, Bortezomib, generates revenues in excess of one billion U.S. dollars per year. However, it also inhibits other important proteins and thus sets off a host of severe side effects. Hence, there is a worldwide search for alternatives.

A variant of the proteasome, the immuno-proteasome, is a leading actor in another vital process: the immune reaction. The production of human insulin in genetically modified bacteria is a boon for diabetes patients. But calculating required doses and injecting insulin on a daily basis is a considerable burden. The transplantation of intact insulin-producing islet cells from pigs could be a solution, but the immune reaction stands in the way. If physicians were able to curb the immuno-proteasome temporarily, they could possibly get the rejection reaction under control.

In both cases, targeting the intervention as specifically as possible is essential to minimizing the damage caused by side effects. Besides Bortezomib two other proteasome inhibitors -- Carfilzomib and Salinosporamide A, derived from a poison produced by a marine bacterium -- are already in the human clinical trial stage. In earlier research, Professor Groll's team succeeded in explaining the mechanism of action of both substances. They follow the same principle, which is considerably more specific than Bortezomib in binding at the desired location in the proteasome and thus produce significantly fewer side effects. Yet, when they take effect, they destroy the proteasomes irreversibly. While healthy cells survive by building up a new proteasome, the fast-growing cancer cells suffocate in their own waste and end up in apoptosis.

The trick of both of these proteasome blockers is a two-step reaction. The tiny molecule fits a specific site on the proteasome like a key going into a lock. However, the reversible docking at the binding site is followed by an irreversible ring formation that prevents the key from being pulled back out. By choosing another head group, Professor Michael Groll und Dr. Melissa Graewert were able to achieve a reversible ring formation. The new head group contains an aldehyde and a keto group in immediate proximity. They also react with the binding sites on the proteasome by forming a ring. However, the reaction of these two groups is reversible: The key can be removed from the lock and the proteasome can resume its work.

Within the framework of their work supported by the Cluster of Excellence Center for Integrated Protein Science Munich (CIPSM), the TUM scientists succeeded in confirming the assumed mechanism using X-ray structure analysis of inhibited proteasome crystals. It also became clear how this binding mechanism could be developed into a drug with fewer side effects. In addition to the head group, the binding mechanism contains a short chain of amino acids that can be designed to fit into the binding pockets of the proteasome. By varying the amino acids, the binding can be optimized to specifically attack immuno-proteasomes.

"The reversible two-step binding mechanism shown here is unique to proteasomes," says Michael Groll, who holds the Chair of Biochemistry at the Department of Chemistry of the Technische Universitaet Mόnchen. "This explains the high selectivity and leads us to expect relatively minor side effects. The reversible reaction opens up a much wider field of application. We can now develop these binding mechanisms further in the direction of immunosuppressive agents." It is precisely this challenge the researchers are now taking on, in close collaboration with physicians, through a new SFB-transregional initiative: "Biology of xenogenic cell and organ transplantation -- from bench to bedside."

This research was funded with grants from the Deutsche Forschungsgemeinschaft (DFG, Cluster of Excellence Center for Integrated Protein Science Munich, CIPSM, and SFB 595) and the Traudl and Peter Engelhorn Foundation (to Melissa Graewert). The X-ray crystallography experiments were performed at the PXI beamline of the Swiss Light Source, Paul Scherrer Institut, Villigen, Switzerland.


Story Source:

The above story is based on materials provided by Technische Universitaet Muenchen. Note: Materials may be edited for content and length.


Journal Reference:

  1. Melissa Ann Grδwert, Nerea Gallastegui, Martin Stein, Boris Schmidt, Peter-Michael Kloetzel, Robert Huber, Michael Groll. Elucidation of the α-Keto-Aldehyde Binding Mechanism: A Lead Structure Motif for Proteasome Inhibition. Angewandte Chemie International Edition, 2010; DOI: 10.1002/anie.201005488

Cite This Page:

Technische Universitaet Muenchen. "Fighting cancer and steering immune reactions: New mechanism for reversible proteasome inhibition." ScienceDaily. ScienceDaily, 27 December 2010. <www.sciencedaily.com/releases/2010/12/101213111441.htm>.
Technische Universitaet Muenchen. (2010, December 27). Fighting cancer and steering immune reactions: New mechanism for reversible proteasome inhibition. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2010/12/101213111441.htm
Technische Universitaet Muenchen. "Fighting cancer and steering immune reactions: New mechanism for reversible proteasome inhibition." ScienceDaily. www.sciencedaily.com/releases/2010/12/101213111441.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) — The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) — Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins